Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 490.77% | 480.98% | 151.33% | -75.29% | -87.32% |
| Gross Profit | -490.77% | -480.98% | -151.33% | 75.29% | 87.32% |
| SG&A Expenses | 37.42% | 41.17% | 33.02% | 19.00% | 8.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.19% | 44.70% | 29.71% | 26.80% | 17.21% |
| Operating Income | -61.19% | -44.70% | -29.71% | -26.80% | -17.21% |
| Income Before Tax | -51.56% | -31.40% | -19.71% | -4.44% | -33.56% |
| Income Tax Expenses | 62.11% | 125.40% | -- | -- | -- |
| Earnings from Continuing Operations | -51.61% | -31.67% | -20.54% | -4.98% | -34.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.61% | -31.67% | -20.54% | -4.98% | -34.11% |
| EBIT | -61.19% | -44.70% | -29.71% | -26.80% | -17.21% |
| EBITDA | -61.25% | -44.77% | -29.79% | -26.78% | -17.20% |
| EPS Basic | 0.13% | 12.11% | 20.18% | 23.86% | -9.58% |
| Normalized Basic EPS | -18.19% | -3.08% | 7.55% | 12.07% | 6.08% |
| EPS Diluted | 0.13% | 12.11% | 20.18% | 23.86% | -9.58% |
| Normalized Diluted EPS | -18.19% | -3.08% | 7.55% | 12.07% | 6.08% |
| Average Basic Shares Outstanding | 44.44% | 45.54% | 50.29% | 38.43% | 26.47% |
| Average Diluted Shares Outstanding | 44.44% | 45.54% | 50.29% | 38.43% | 26.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |